Acalabrutinib in patients (pts) with Waldenström macroglobulinemia (WM).
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2018.36.15_suppl.7501
Abstract: 7501Background: Bruton tyrosine kinase (BTK) is a clinically validated target in WM. Acalabrutinib is a highly selective, potent, covalent BTK inhibitor that we evaluated in a Phase 2 study of pts ... read more here.
Keywords: waldenstr macroglobulinemia; pts waldenstr; acalabrutinib; acalabrutinib patients ... See more keywords